

Chaurasia V, Kumar V, Jain D. Sumatriptan succinate loaded microspheres containing compressed core tablets for effective treatment of migraine. *Bull. Pharm. Res.* 2016;6(2): 56-67.

### References (39):

1. Bandari S, Mittapalli RK, Gannu R, Rao YM. Orodispersible tablets: an overview. *Asian J. Pharm.* 2008;2:2-11.  
<http://www.asiapharmaceutics.info/index.php/ajp/article/viewFile/159/161>
2. Basarkar GD, Shirsath GN, Patil SB. Development of microspheres containing diclofenac diethylamine as sustained release topical formulation. *Bull. Pharm. Res.* 2013;3(1):14-22.  
<https://www.appconnect.in/wp-content/uploads/2011/03/ReprintBPR0662.pdf>
3. Chaturvedi AK, Verma A. Fast disintegrating tablet technology: newly prospects. *Int. J. Pharm. Sci. Res.* 2011;2(12):3046-50.  
<http://ijpsr.com/bft-article/fast-disintegrating-tablet-technology-newly-prospects/?view=fulltext>
4. Dahiya S, Gupta ON. Formulation and *in vitro* evaluation of metoprolol tartrate microspheres. *Bull. Pharm. Res.* 2011;1(1):31-9.  
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR007.pdf>
5. Dahiya S, Tyagi L. Preparation and evaluation of oxytetracycline hydrochloride microbeads for delayed release. *Pak. J. Pharm. Sci.* 2008;21(2):103-8.  
<http://www.pjps.pk/wp-content/uploads/pdfs/CD-PJPS-21-2-08/Paper-4.pdf>
6. Dahlof C. Update on sumatriptan: new progress in migraine treatment. *Therapy* 2005; 2(3):349-356.  
<http://www.futuremedicine.com/doi/abs/10.2217/14750708.2.3.349?journalCode=thy>
7. Dandge BH, Dehghan MHG, Gaikwad VM. Preparation and characterization of mucoadhesive microparticles of sumatriptan succinate for intranasal delivery. *J. Pharm. Res.* 2009;2(9): 1536-1539.  
<http://jpr solutions.info/newfiles/journal-file-56b422f3c8af30.92197933.pdf>
8. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. *Eur. J. Neurol.* 2009; 16(9):968-981.  
<https://www.ncbi.nlm.nih.gov/pubmed/19708964>
9. Farshid A, Rama B, Muralidharan G, Nargund LVG. Formulation and evaluation of orodispersible tablets of zolmitriptan. *Asian J. Pharm. Clin. Res.* 2014;7(1):127-134.  
<http://innovareacademics.in/journals/index.php/ajpcr/article/view/847/561>

10. Gandhi A. Mouth dissolving tablets: a new venture in modern formulation technology. *Pharma Innov.* 2012;1(8):14-21.  
<http://search.proquest.com/openview/81044a755110882cb1e229d069971971/1?pq-origsite=gscholar>
11. Jain D, Banerjee R. Comparison of Ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2008;86(1):105-112.  
<https://www.ncbi.nlm.nih.gov/pubmed/18098198>
12. Kannuri R, Challa T, Chamarthi H. Taste masking and evaluation methods for orodispersible tablets. *Int. J. Pharm. Ind. Res.* 2011;1(3):200-10.  
[http://www.ijpir.com/zip.php?file=File\\_Folder/09%20TASTE%20MASKING%20AND%20EVALUATION%20METHODS.pdf&id=66&quat=1](http://www.ijpir.com/zip.php?file=File_Folder/09%20TASTE%20MASKING%20AND%20EVALUATION%20METHODS.pdf&id=66&quat=1)
13. Kela SP, Kesharwani D. Formulation, characterization and evaluation of taste masked rapid disintegrating tablet of ofloxacin by ion exchange resin technique. *Int. J. Pharm. Sci. Rev. Res.* 2013;21(2):246-53.  
<http://globalresearchonline.net/journalcontents/v21-2/45.pdf>
14. Khoury CK, Couch JR. Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. *Drug Des. Devel. Ther.* 2010;4:9-17.  
<https://www.ncbi.nlm.nih.gov/pubmed/20368903>
15. Kumar M, Dureja H. Development and characterization of factorially designed 5-fluorouracil microspheres. *Bull. Pharm. Res.* 2011;1(1):54-61.  
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR010.pdf>
16. Kumar PR, Doddayya H, Reddy SR. Design and evaluation studies on novel floating tablets for peptic ulcer treatment. *J. Adv. Pharm. Edu. Res.* 2011;2:159-176.  
<http://www.japer.in/issue/issues%203%20september/33.pdf>
17. Listos J, Budzynska B, Orzelska J. New advances in pharmacotherapy of migraine. *J. Analg.* 2013;1(1):18-25.  
<http://www.pharmapublisher.com/jms/index.php/jta/article/view/131>
18. Lopes CM, Lobo JM, Pinto JF, Costa PC. Compressed matrix core tablet as a quick/slow dual-component delivery system containing Ibuprofen. *AAPS PharmSciTech* 2007;8(3):E76.  
<https://www.ncbi.nlm.nih.gov/pubmed/17915826>
19. Majeed SM, Khalil YI. Formulation and evaluation of bilayer matrix tablets of amoxicillin and esomeprazole as an oral modified release dosage form for treatment of peptic ulcer. *Int. J. Pharm. Pharm. Sci.* 2014;6(3):134-42.  
<http://www.ijppsjournal.com/Vol6Issue3/8927.pdf>

20. Mohammad S, Mohammad S, Srinivas B, Begum A. Evaluation of tablets by friability apparatus. *Int. J. Res. Pharm. Chem.* 2014;4(4):837-40.  
<http://www.ijrpc.com/files/12-4170.pdf>
21. Nagar M, Yadav AV. Cinnarizine orodispersible tablets: a chitosan based fast mouth dissolving technology. *Int. J. PharmTech Res.* 2009;1(4):1079-91.  
[http://sphinxesai.com/ptvol4/pdf\\_vol4/pt=18%20\(1079-1091\).pdf](http://sphinxesai.com/ptvol4/pdf_vol4/pt=18%20(1079-1091).pdf)
22. Parashar B, Yadav V, Maurya B, Sharma L. Fast dissolving tablet. *Int. J. Appl. Pharm.* 2012;4(2):17-22.  
<http://www.ijaponline.org/Vol4Issue2/117.pdf>
23. Patel NJ, Lakshmi CSR, Patel HP, Akul S. Formulation and evaluation of oral dispersible tablets of cinnarizine using direct compression technique. *Int. J. Pharm. Sci. Res.* 2011; 2(4):961-7.  
<http://ijpsr.com/bft-article/formulation-and-evaluation-of-oral-dispersible-tablets-of-cinnarizine-using-direct-compression-technique/?view=fulltext>
24. Patil MR, Gujarathi NA, Rane BR. Formulation and evaluation of mouth dissolving tablet: review article. *Pharm. Sci. Monitor* 2014;5(2):7-20.  
[http://www.pharmasm.com/pdf\\_files/20140430130805\\_02\\_mayuri.pdf](http://www.pharmasm.com/pdf_files/20140430130805_02_mayuri.pdf)
25. Ponugoti RSR, Gonugunta CR. Formulation and evaluation of mouth dissolving tablets of tramadol hydrochloride. *Trop. J. Pharm. Res.* 2014;13(5):669-75.  
[http://www.tjpr.org/vol13\\_no5/2014\\_13\\_5\\_3.pdf](http://www.tjpr.org/vol13_no5/2014_13_5_3.pdf)
26. Rahman Z, Kohli K, Khar RK, Ali M, Charoo NA, Shamsheer AAA. Characterization of 5-fluorouracil microspheres for colonic delivery. *AAPS PharmSciTech* 2006;7(2):113-121.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750274>
27. Rao KS, Patil KG, Dattatreya BU, Patil PS, Biradar KV. Design and evaluation of orodispersible tablets of sumatriptan succinate. *RGUHS J. Pharm. Sci.* 2012;2(3):41-7.  
<http://www.rjps.in/article/46>
28. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. *CNS Drugs* 2010;24(11):929-40.  
<https://www.ncbi.nlm.nih.gov/pubmed/20932065>
29. Rubingh C. Preventive therapy for migraine headache. *Adv. Stud. Pharm.* 2007;4(1):15-20.
30. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. *Pain* 1998;76(1-2):3-8.  
<http://www.sciencedirect.com/science/article/pii/S0304395998000335>

31. Samineni R, Ramakrishna G, Balaji M, Kondala Rao K. Formulation and evaluation of sumatriptan succinate mouth disintegrating tablets. *Am. J. Adv. Drug. Deliv.* 2013;1(5): 759-69.  
<http://www.imedpub.com/articles/formulation-and-evaluation-of-sumatriptan-succinate-mouth-disintegrating-tablets.pdf>
32. Sharma D, Kumar D, Singh M, Singh G, Rathore MS. Fast disintegrating tablets: a new era in novel drug delivery system and new market opportunities. *J. Drug Del. Ther.* 2012;2(3): 74-86.  
<http://jddtonline.info/index.php/jddt/article/viewFile/125/89>
33. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice, 2nd edition, CRC Press: London, 2002; 797-804.  
<https://www.amazon.com/Headache-Clinical-Practice-Stephen-Silberstein/dp/1901865886>
34. Terry RS, Wernicke JF, Baker RG. Therapeutic treatment migraine symptoms by stimulation. US Patent 1993 [Patent number US 5215086 A].  
<http://www.google.tt/patents/US5215086>
35. Tripathi KD. Essentials of Medical Pharmacology, 6<sup>th</sup> edition, Jaypee Brothers Medical Publishers(P) Ltd: New Delhi, 2009; 169-172.  
[https://docs.google.com/file/d/0Bxvjl4mG\\_bfYT1h4Z1FnalhfVWs/edit?pli=1](https://docs.google.com/file/d/0Bxvjl4mG_bfYT1h4Z1FnalhfVWs/edit?pli=1)
36. Tripathi M, Radhika PR, Sivakumar T. Formulation and evaluation of glipizide hollow microballoons for floating drug delivery. *Bull. Pharm. Res.* 2011;1(1):67-74.  
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR0121.pdf>
37. Vikelis M, Mitsikostas DD, Rapoport AM. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. *Neuropsychiatr. Dis. Treat.* 2012;8:429-434.  
<https://www.ncbi.nlm.nih.gov/pubmed/23055737>
38. Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. *Proc. West. Pharmacol. Soc.* 2002;45:199-210.  
<https://www.ncbi.nlm.nih.gov/pubmed/12434581>
39. Verma S, Kumar V, Jyoti, Mishra DN. Formulation, evaluation and optimization of mucoadhesive microspheres of acyclovir. *Bull. Pharm. Res.* 2014;4(1):14-20.  
<http://journal.appconnect.in/wp-content/uploads/2014/05/ReprintBPR087.pdf>